Regeneron Pharmaceuticals (REGN) said Wednesday that the US Food and Drug Administration has accepted for review the resubmission of its biologics license application for odronextamab drug, a treatment for relapsed/refractory follicular lymphoma after two or more lines of systemic therapy.
The target action date for the agency's decision is July 30, the company said.
The acceptance of the resubmission follows the achievement of target mandated by the agency in a confirmatory trial. The resubmission is supported by data from two trials, which showed that the drug had an overall response rate of 80% and a 74% complete response rate, the company said.
Follicular lymphoma is one of the most common subtypes of B-cell non-Hodgkin lymphoma.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.